(Q43017536)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20554235%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

title

Inhibition of glycogen biosynthesis via mTORC1 suppression as an adjunct therapy for Pompe disease (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20554235%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20554235%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

13

Robert J Mattaliano

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20554235%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

author name string

Karen M Ashe

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20554235%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

Kristin M Taylor

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20554235%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

Qiuming Chu

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20554235%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

Elizabeth Meyers

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20554235%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

Allen Ellis

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20554235%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

Varvara Jingozyan

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20554235%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

Katherine Klinger

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20554235%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

Patrick F Finn

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20554235%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

Christopher G F Cooper

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20554235%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

Wei-Lien Chuang

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20554235%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

John M McPherson

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20554235%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

Seng H Cheng

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20554235%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

Ronald K Scheule

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20554235%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

Rodney J Moreland

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20554235%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

publication date

5 May 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20554235%20AND%20SRC:MED&resulttype=core&format=json

Molecular Genetics and Metabolism

5 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20554235%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

volume

100

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20554235%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20554235%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

page(s)

309-315

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20554235%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.001

Enzyme replacement therapy in classical infantile pompe disease: results of a ten-month follow-up study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.001

Glycogen storage disease types I and II: treatment updates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.001

Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.001

Morphological changes in muscle tissue of patients with infantile Pompe's disease receiving enzyme replacement therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.001

Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.001

Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.001

Early treatment with alglucosidase alpha prolongs long-term survival of infants with Pompe disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.001

Pompe disease: a neuromuscular disease with respiratory muscle involvement

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.001

Imino sugar inhibitors for treating the lysosomal glycosphingolipidoses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.001

Restoration of muscle functionality by genetic suppression of glycogen synthesis in a murine model of Pompe disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.001

Modulation of glycogen synthesis by RNA interference: towards a new therapeutic approach for glycogenosis type II.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.001

Targeted disruption of the acid alpha-glucosidase gene in mice causes an illness with critical features of both infantile and adult human glycogen storage disease type II

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.001

Regulation of both glycogen synthase and PHAS-I by insulin in rat skeletal muscle involves mitogen-activated protein kinase-independent and rapamycin-sensitive pathways

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.001

Control of glycogen synthesis in cultured human muscle cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.001

Rapamycin-mediated inhibition of mammalian target of rapamycin in skeletal muscle cells reduces glucose utilization and increases fatty acid oxidation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.001

Regulation of glycogen synthesis by amino acids in cultured human muscle cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.001

The TSC-mTOR pathway mediates translational activation of TOP mRNAs by insulin largely in a raptor- or rictor-independent manner

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.001

Targeting mammalian target of rapamycin (mTOR) for health and diseases.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.001

Upstream and downstream of mTOR

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.001

Regulation of muscle glycogen synthase phosphorylation and kinetic properties by insulin, exercise, adrenaline and role in insulin resistance.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.001

Muscle inactivation of mTOR causes metabolic and dystrophin defects leading to severe myopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.001

Bifurcation of insulin signaling pathway in rat liver: mTORC1 required for stimulation of lipogenesis, but not inhibition of gluconeogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.001

Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.001

Glycoengineered acid alpha-glucosidase with improved efficacy at correcting the metabolic aberrations and motor function deficits in a mouse model of Pompe disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.001

mTOR and the control of whole body metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.001

Elimination of antibodies to recombinant enzyme in Pompe's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.001

Suppression of autophagy in skeletal muscle uncovers the accumulation of ubiquitinated proteins and their potential role in muscle damage in Pompe disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.001

FoxO3 controls autophagy in skeletal muscle in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.05.001